Immunotherapy Trials: Overcoming the Challenges of Selecting the Correct Patient Population

There are lots of immunotherapies currently being tested in oncology trials and they are one of the leading forces in oncology drug trials throughout North America and the World. The marketplace is teaming with “the latest” and “the greatest” immunotherapies, but do they work in practice? How can they be brought to market in a practical, cost-efficient manner, that pays due respect to the commercial objectives of the sponsor, and the treatment imperatives of the patient?

One of America’s foremost oncologists leads this webinar series on the past, the present and the future of immunotherapy studies. Dr. VanderWalde will give you a no-holds-barred perspective of the trials of the past, how they worked, and insight into successes and failures of those earlier trials. He will use present-day case studies that represent the current landscape and highlight the logistics and challenges that come with running an efficient precision medicine trial. Finally, he will discuss the future of immunotherapy trials: basket/umbrella trials and the most effectual approach to bring the latest and greatest compounds to market. All of this will be based on tried and true experience.

Do not miss this live webinar if you are the CMO, CEO, COO, Clinical Operations Leader, Outsourcing/Procurement Leader or CSO of pharmaceutical, biotech or organizations with a cellular therapy compound in their pipeline.

Dr. Vanderwalde offers a unique perspective as a clinician, as a medical leader for an oncology CRO, who has had an extensive career at the forefront throughout the rise of immunotherapy trials.

Dr. VanderWalde will discuss the current and future landscape, along with the benefits of various immunotherapy trial designs, including basket/umbrella trials.

Attendees will:

• Gain firsthand knowledge of the history and growth of cell therapy trials, their challenges, and their benefits
• Learn about the future of cell therapy trials and the impact on sponsors and patients
• Gain insight into the development of efficacious trial design and how partnering with scientific leadership early in the planning stage assists throughout the development process

Speaker

Ari VanderWalde, MD, MPH, FACP, scientific leader at George Clinical CRO, Director of Clinical Research at West Cancer Center, Associate Vice Chancellor of Clinical Research at University of Tennessee Health Science Center

Ari VanderWalde is a scientific leader at George Clinical (oncology CRO), the Director of Clinical Research at West Cancer Center and Associate Vice Chancellor of Clinical Research at University of Tennessee Health Science Center. He is a board-certified medical oncologist and assistant professor in the Division of Hematology/Oncology. With expertise in clinical research, immunotherapy, molecular-targeted therapy, and melanoma, Dr. VanderWalde chairs the Research Subcommittee of the Executive Cancer Council and the Multidisciplinary Cutaneous Cancer Conference and co-chairs the Molecular Oncology Tumor Board. He is responsible for managing the portfolio for all clinical research studies occurring at West Cancer Center and serves as Primary Investigator or Subinvestigator on all externally sponsored trials.

Before joining West Cancer Center, Dr. VanderWalde served as U.S. Medical Lead and Medical Director at Amgen, directing U.S. global development of novel immunotherapeutics in melanoma. As an expert in melanoma, Dr. VanderWalde has collaborated with many of the nation’s top thought leaders.

Dr. VanderWalde’s vision is to take novel promising therapies and translate them systematically and efficiently into agents that achieve tangible benefits for people with cancer.

Dr. VanderWalde will be attending and presenting an abstract at ASCO. If you would like to schedule a meeting with him to answer additional questions or advise on your oncology program, click here.

Message Presenter